Group 1 - The core point of the article is that Codex Group (stock code: 2487) announced a share placement to raise approximately HKD 240 million through the issuance of 28,904,000 new shares at a price of HKD 8.40 per share, which represents a discount of about 12.0% from the previous closing price of HKD 9.55 [1] - The placement shares represent approximately 9.1% of the existing issued share capital and about 8.3% of the enlarged share capital after completion [1] - The placement is managed by BOC International and Haitong International as placement agents, and the completion is expected by September 5, 2025 [1] Group 2 - Codex Group is an investment holding company focused on developing innovative and comprehensive solutions to meet the diverse and evolving needs of patients and consumers in the dermatology treatment and care market [2] - Approximately HKD 110 million of the raised funds will be allocated for preclinical research and clinical trials related to local fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [2] - Another HKD 110 million will be used for marketing activities, channel expansion, and brand building for CU - 40102 (topical finasteride spray) and CU - 10201 (topical 4% minocycline foam) [2] - The remaining HKD 20 million will be allocated for working capital and other general corporate purposes [2]
科笛集团 ：通过一般授权配售新股募资约 2.4 亿港元 研发及市场推广